Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mind Medicine (MindMed) Inc.

13.65
+1.7414.61%
Post-market: 13.910.2600+1.90%19:59 EDT
Volume:3.79M
Turnover:49.05M
Market Cap:1.04B
PE:-9.53
High:13.86
Open:11.67
Low:11.56
Close:11.91
52wk High:13.86
52wk Low:4.70
Shares:76.09M
Float Shares:70.25M
Volume Ratio:1.86
T/O Rate:5.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4323
EPS(LYR):-1.5424
ROE:-59.11%
ROA:-30.55%
PB:5.60
PE(LYR):-8.85

Loading ...

A Fresh Look at MindMed (MNMD) Valuation After Breakthrough Phase 2b Results and FDA Recognition

Simply Wall St.
·
11 hours ago

MindMed Grants Stock Options to New Employee as Part of Inducement Compensation Plan

Reuters
·
Oct 15

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Benzinga_recent_news
·
Oct 14

Needham Initiates Mind Medicine (MindMed) at Buy With $28 Price Target

MT Newswires Live
·
Oct 13

Mind Medicine MindMed Initiated at Buy by Needham

Dow Jones
·
Oct 13

Mind Medicine (MindMed) Inc : Needham Initiates Coverage With Buy Rating; Target Price $28

THOMSON REUTERS
·
Oct 13

Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD) and OKYO Pharma Limited Sponsored ADR (OKYO)

TIPRANKS
·
Sep 23

MindMed Announces Inducement Grants for New Employees with Options to Purchase 182,800 Shares

Reuters
·
Sep 23

Psychedelic: Exclusive talk with biopharma company MindMed

TIPRANKS
·
Sep 18

MindMed Announces Inducement Grants for New Employees with Options Vesting Over Four Years

Reuters
·
Sep 09

MindMed Unveils Strategic Focus on GAD and MDD with Late-Stage Pipeline and Innovation in Brain Health

Reuters
·
Sep 05

MindMed Announces Positive Results from Phase 2b Trial of MM120 for Treating Generalized Anxiety Disorder, Published in JAMA

Reuters
·
Sep 04

Journal of the American Medical Association (Jama) Publishes Results From First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of Mm120 (Lysergide D-Tartrate, Lsd) in Generalized Anxiety Disorder (Gad)

THOMSON REUTERS
·
Sep 04

Optimi Health Corp. Secures Regulatory Approval for Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression

Reuters
·
Sep 03

Mind Medicine (MindMed) Inc. to Participate in Cantor Global Healthcare Conference 2025

Reuters
·
Aug 28

MindMed Announces New Employee Compensation Plan with Inducement Grants and Performance Share Units

Reuters
·
Aug 12

MindMed Q2 2025 Earnings Call Summary and Q&A Highlights: Advancing Pivotal Trials and Strategic Growth

Earnings Call
·
Aug 11

Stock Track | Mind Medicine (MindMed) Soars 6.87% After Oppenheimer's Bullish $25 Price Target

Stock Track
·
Aug 05

Stock Track | Mind Medicine (MindMed) Soars 6.61% Pre-market on Oppenheimer's Outperform Rating and $25 Price Target

Stock Track
·
Aug 04

Mind Medicine MindMed Price Target Announced at $25.00/Share by Oppenheimer

Dow Jones
·
Aug 04